Muik, A., Altintas, I., Kosoff, R., Gieseke, F., Schödel, K., Salcedo, T., Burm, S., Toker, A., Kranz, L., Vormehr, M., Eisel, D., Fereshteh, M., Türeci, Ö., Breij, E., Ahmadi, T., Sahin, U., & Jure-Kunkel, M. (n.d.). 561 DuoBody®-PD-L1×4–1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4–1BB co-stimulation. Journal for immunotherapy of cancer, 8, A338–A339. http://access.bl.uk/ark:/81055/vdc_100144719863.0x000002